Experience of piloting BPaLM/BPaL for DR-TB care at selected sites in Pakistan.

ABSTRACT:

Background

Pakistan ranks fourth globally in terms of high drug-resistant TB (DR-TB) burden, with approximately one-third of cases resistant to fluoroquinolones. Bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM/BPaL) offers an opportunity for most DR-TB patients to benefit from a shorter, all-oral, well-tolerated and more effective treatment.

Methods

We conducted a retrospective cohort study to pilot the BPaLM/BPaL regimen at four selected sites in two provinces of Pakistan, i.e. Punjab and Khyber Pakhtunkhwa. Data were extracted and analysed using electronic medical records from the program. Descriptive statistics, survival analysis and binary logistic regression analysis were employed.

Results

A total of 116 patients took treatment between October 2022 and

SUBMITTER: Khan MA 

PROVIDER: S-EPMC11558782 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature